Literature DB >> 31504677

Tau Phosphorylation and Aggregation in the Developing Human Brain.

Marco M Hefti1,2,3, SoongHo Kim2,4,5, Aaron J Bell2,6, Ryan K Betters3, Kimberly L Fiock1, Megan A Iida2,4,5, Martin E Smalley1, Kurt Farrell2,4,5, Mary E Fowkes2, John F Crary2,4,5.   

Abstract

Tau hyperphosphorylation, mostly at serine (Ser) or threonine (Thr) residues, plays a key role in the pathogenesis of Alzheimer disease (AD) and other tauopathies. Rodent studies show similar hyperphosphorylation in the developing brain, which may be involved in regulating axonal growth and plasticity, but detailed human studies are lacking. Here, we examine tau phosphorylation by immunohistochemistry and immunoblotting in human fetal and adult autopsy brain tissue. Of the 20 cases with sufficient tissue preservation, 18 (90%) showed positive staining for S214 (pSer214), with the majority also positive for CP13 (pSer202), and PHF-1 (pSer396/pSer404). AT8 (pSer202/pThr205) and RZ3 (pThr231) were largely negative while PG5 (pSer409) was negative in all cases. Immunoblotting showed tau monomers with a similar staining pattern. We also observed phospho-tau aggregates in the fetal molecular layer, staining positively for S214, CP13, and PHF1 and negative for thioflavin S. These corresponded to high-molecular weight (∼150 kD) bands seen on Western blots probed with S214, PHF1, and PG5. We therefore conclude that fetal phosphorylation overlaps with AD in some residues, while others (e.g. T231, S409) appear to be unique to AD, and that tau is capable of forming nontoxic aggregates in the developing brain. These findings suggest that the fetal brain is resilient to formation of toxic aggregates, the mechanism for which may yield insights into the pathogenesis of tau aggregation and toxicity in the aging brain.
© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Brain development; Oligomers; Phosphorylation; Protein aggregation; Tau protein

Mesh:

Substances:

Year:  2019        PMID: 31504677      PMCID: PMC6751069          DOI: 10.1093/jnen/nlz073

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  43 in total

1.  Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice.

Authors:  S Ikegami; A Harada; N Hirokawa
Journal:  Neurosci Lett       Date:  2000-02-04       Impact factor: 3.046

2.  Isoforms changes of tau protein during development in various species.

Authors:  Hiroshi Takuma; Shigeki Arawaka; Hiroshi Mori
Journal:  Brain Res Dev Brain Res       Date:  2003-05-14

3.  Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding.

Authors:  Jae-Hyeon Cho; Gail V W Johnson
Journal:  J Biol Chem       Date:  2002-10-29       Impact factor: 5.157

4.  Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.

Authors:  R Benavides-Piccione; M Dierssen; I Ballesteros-Yáñez; M Martínez de Lagrán; M L Arbonés; V Fotaki; J DeFelipe; G N Elston
Journal:  Neurobiol Dis       Date:  2005-10       Impact factor: 5.996

5.  cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease.

Authors:  G A Jicha; C Weaver; E Lane; C Vianna; Y Kress; J Rockwood; P Davies
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

6.  The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains.

Authors:  J Biernat; E M Mandelkow
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

7.  The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting.

Authors:  Georgina M Aldridge; David M Podrebarac; William T Greenough; Ivan Jeanne Weiler
Journal:  J Neurosci Methods       Date:  2008-05-15       Impact factor: 2.390

8.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.

Authors:  Fei Liu; Zhihou Liang; Jerzy Wegiel; Yu-Wen Hwang; Khalid Iqbal; Inge Grundke-Iqbal; Narayan Ramakrishna; Cheng-Xin Gong
Journal:  FASEB J       Date:  2008-05-28       Impact factor: 5.191

9.  DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.

Authors:  Soo-Ryoon Ryoo; Hey Kyeong Jeong; Chinzorig Radnaabazar; Jin-Ju Yoo; Hyun-Jeong Cho; Hye-Won Lee; In-Sook Kim; Young-Hee Cheon; Young Soo Ahn; Sul-Hee Chung; Woo-Joo Song
Journal:  J Biol Chem       Date:  2007-09-28       Impact factor: 5.157

10.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice.

Authors:  H N Dawson; A Ferreira; M V Eyster; N Ghoshal; L I Binder; M P Vitek
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

View more
  12 in total

1.  Cornel Iridoid Glycoside Regulates Modification of Tau and Alleviates Synaptic Abnormalities in Aged P301S Mice.

Authors:  Cui-Cui Yang; Yi Luo; Kai-Wen Guo; Ceng-Ceng Zheng; Lin Li; Lan Zhang
Journal:  Curr Med Sci       Date:  2021-01-11

2.  Mice expressing P301S mutant human tau have deficits in interval timing.

Authors:  Travis Larson; Vaibhav Khandelwal; Matthew A Weber; Mariah R Leidinger; David K Meyerholz; Nandakumar S Narayanan; Qiang Zhang
Journal:  Behav Brain Res       Date:  2022-06-17       Impact factor: 3.352

3.  Reduction of pTau and APP levels in mammalian brain after low-dose radiation.

Authors:  Diego Iacono; Erin K Murphy; Soundarya S Avantsa; Daniel P Perl; Regina M Day
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.996

4.  Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology.

Authors:  Antoine Duquette; Camille Pernègre; Ariane Veilleux Carpentier; Nicole Leclerc
Journal:  Front Neurol       Date:  2021-01-07       Impact factor: 4.003

Review 5.  Disrupting Neurons and Glial Cells Oneness in the Brain-The Possible Causal Role of Herpes Simplex Virus Type 1 (HSV-1) in Alzheimer's Disease.

Authors:  Matylda Barbara Mielcarska; Katarzyna Skowrońska; Zbigniew Wyżewski; Felix Ngosa Toka
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

Review 6.  Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration.

Authors:  Ben Boyarko; Vivian Hook
Journal:  Front Neurosci       Date:  2021-10-21       Impact factor: 4.677

Review 7.  Early-Life Environment Influence on Late-Onset Alzheimer's Disease.

Authors:  Thibaut Gauvrit; Hamza Benderradji; Luc Buée; David Blum; Didier Vieau
Journal:  Front Cell Dev Biol       Date:  2022-02-17

Review 8.  Phosphorylated tau as a toxic agent in synaptic mitochondria: implications in aging and Alzheimer's disease.

Authors:  Angie K Torres; Bastián I Rivera; Catalina M Polanco; Claudia Jara; Cheril Tapia-Rojas
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

9.  Increased Tau Expression Correlates with Neuronal Maturation in the Developing Human Cerebral Cortex.

Authors:  Kimberly L Fiock; Martin E Smalley; John F Crary; Anca M Pasca; Marco M Hefti
Journal:  eNeuro       Date:  2020-05-28

10.  Sleep Quality Improvement Enhances Neuropsychological Recovery and Reduces Blood Aβ42/40 Ratio in Patients with Mild-Moderate Cognitive Impairment.

Authors:  Haihua Huang; Mingqiu Li; Menglin Zhang; Jiang Qiu; Haiyan Cheng; Xin Mou; Qinghong Chen; Tina Li; Jun Peng; Benyi Li
Journal:  Medicina (Kaunas)       Date:  2021-12-15       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.